Tioga Cardiovascular

Tioga Cardiovascular is an early-stage, pre-revenue medical device innovator targeting the large and underserved market for transcatheter mitral valve replacement (TMVR). Its core technology is the Tioga TMVR System, which features a unique two-component design—a valve with a large atrial brim and a separate anchor that captures the native chordae—aimed at reducing paravalvular leak and left ventricular outflow tract obstruction risks. As a portfolio company of Shifamed, Tioga leverages experienced leadership from the medtech industry but faces significant clinical, regulatory, and competitive hurdles common to novel cardiovascular device development.

A two-component transcatheter mitral valve replacement (TMVR) system featuring a valve with a large atrial brim for sealing and a separate, repositionable anchor designed to capture the native chordae tendineae for stabilization. Delivered via low-profile, steerable 28 French catheter systems.

Tioga competes in the transcatheter mitral intervention space, primarily against the dominant TEER devices (Abbott's MitraClip, Edwards' PASCAL) and a growing field of TMVR developers like Edwards Lifesciences (SAPIEN M3), Medtronic, Abbott, and startups such as Cardiovalve, Venus Medtech, and others. Success requires differentiating on safety, ease of use, and anatomical applicability.